文献速递肾癌与肾肿瘤

cT1肾肿块行肾部分切除术与经皮消融后的肿瘤学结局

Oncologic Outcomes Following Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses.
PubMed 文献 · Eur Urol · 2019-05-03

梅奥诊所2000至2011年1798例cT1N0M0肾肿块患者的回顾性研究,比较肾部分切除术(PN)与经皮射频消融(RFA)及冷冻消融的肿瘤学结局。cT1a患者中PN、RFA与冷冻消融的5年癌症特异性生存率分别为99%、96%与100%,局部复发、转移与肾细胞癌死亡的校正风险比均未达统计学显著。cT1b患者中冷冻消融的肾细胞癌死亡更常见,5年癌症特异性生存率PN为98%而冷冻消融为91%,该结局的大差异不能排除,需进一步研究确认冷冻消融在cT1b中的肿瘤学有效性。

要点

  • cT1a患者中PN与RFA或冷冻消融的局部复发、转移及肾细胞癌死亡风险比均未达统计学显著。
  • cT1a的5年癌症特异性生存率PN为99%、RFA为96%、冷冻消融为100%。
  • cT1b患者中冷冻消融的肾细胞癌死亡更常见,5年癌症特异性生存率PN为98%而冷冻消融为91%。

核心结论

  • 在单中心成熟随访下,经皮消融对cT1肾肿瘤似乎结果可接受,适用于有手术禁忌证的患者。
  • cT1a患者中PN与消融的临床相关差异不太可能,治疗选择应共同决策。
  • cT1b患者中冷冻消融的肾细胞癌死亡更常见,该结局的大差异不能排除。
  • 需进一步研究确认冷冻消融在cT1b中的肿瘤学有效性。

研究设计与样本

  • 回顾性识别2000至2011年在梅奥诊所治疗的1798例原发性cT1N0M0肾肿块患者,比较经皮消融与PN。
  • cT1a患者1422例中,1055例行PN、180例行RFA、187例行冷冻消融,中位临床随访分别为9.4年、7.5年与6.3年。
  • cT1b患者376例中,324例行PN、52例行冷冻消融,中位临床随访分别为8.7年与6.0年。

主要发现

  • cT1a中RFA与PN比较,局部复发HR 1.49(95%CI 0.55-4.04,p=0.4)、转移HR 1.46(95%CI 0.41-5.19,p=0.6)、肾细胞癌死亡HR 1.99(95%CI 0.29-13.56,p=0.5)。
  • cT1a中冷冻消融与PN比较,局部复发HR 1.88(95%CI 0.76-4.66,p=0.18)、转移HR 0.23(95%CI 0.03-1.72,p=0.15)、肾细胞癌死亡HR 0.29(95%CI 0.01-6.11,p=0.4)。
  • cT1a的5年癌症特异性生存率PN为99%、RFA为96%、冷冻消融为100%。
  • cT1b中冷冻消融与PN比较,局部复发HR 1.22(95%CI 0.33-4.48,p=0.8)、转移HR 0.95(95%CI 0.21-4.38,p>0.9)、肾细胞癌死亡HR 1.94(95%CI 0.42-8.96,p=0.4)。
  • cT1b的5年癌症特异性生存率PN为98%、冷冻消融为91%。

临床怎么用

  • 经皮消融似乎适用于有手术禁忌证的cT1肾肿瘤患者。
  • cT1a患者的治疗选择应涉及共同决策。
  • 作者指出需进一步研究确认冷冻消融在cT1b中的肿瘤学有效性。

局限性

  • 局限性包括回顾性回顾与选择偏倚。
  • 需进一步研究确认冷冻消融在cT1b中的肿瘤学有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term data comparing partial nephrectomy (PN) and thermal ablation are lacking. OBJECTIVE: To update our experience with PN, percutaneous radiofrequency ablation (RFA), and percutaneous cryoablation for cT1 renal masses. DESIGN, SETTING, AND PARTICIPANTS: A total of 1798 patients with primary cT1N0M0 renal masses treated between 2000 and 2011 at Mayo Clinic were identified. INTERVENTION: Percutaneous ablation versus PN. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Cancer-specific survival (CSS) was estimated using the Kaplan-Meier method. Local recurrence, metastases, and death from renal cell carcinoma (RCC) were compared with propensity-score-adjusted Cox models. RESULTS AND LIMITATIONS: Among 1422 cT1a patients, 1055, 180, and 187 underwent PN, RFA, and cryoablation with median clinical follow-up of 9.4, 7.5, and 6.3yr, respectively. Comparisons of RFA with PN resulted in hazard ratios (HRs) of 1.49 (95% confidence interval [CI] 0.55-4.04, p=0.4), 1.46 (95% CI 0.41-5.19, p=0.6), and 1.99 (95% CI 0.29-13.56, p=0.5) for local recurrence, metastases, and death from RCC. Comparisons of cryoablation to PN resulted in HRs of 1.88 (95% CI 0.76-4.66, p=0.18), 0.23 (95% CI 0.03-1.72, p=0.15), and 0.29 (95% CI 0.01-6.11, p=0.4) for these same outcomes. Five-year CSS was 99%, 96%, and 100% for PN, RFA, and cryoablation, respectively. Among 376 cT1b patients, 324 and 52 underwent PN and cryoablation with median clinical follow-up of 8.7 and 6.0yr, respectively. Comparisons of cryoablation with PN resulted in HRs of 1.22 (95% CI 0.33-4.48, p=0.8), 0.95 (95% CI 0.21-4.38, p>0.9), and 1.94 (95% CI 0.42-8.96, p=0.4) for local recurrence, metastases, and death from RCC, respectively. Five-year CSS was 98% and 91% for PN and cryoablation, respectively. Limitations include retrospective review and selection bias. CONCLUSIONS: With mature follow-up at a single institution, percutaneous ablation appears to have acceptable results for cT1 renal tumors and is appropriate for patients with a contraindication for surgery. For cT1a patients, clinically relevant differences between PN and ablation are unlikely, and treatment choice should involve shared decision making. For cT1b patients, death from RCC was more common with cryoablation, and large differences in this outcome cannot be ruled out. Further research is needed to confirm the oncologic effectiveness of cryoablation in the cT1b setting. PATIENT SUMMARY: With appropriate patient triage, partial nephrectomy and percutaneous ablation can be used to treat cT1 renal masses, although additional follow-up and further study are still needed.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Andrews JR, Atwell T, Schmit G, et al. Oncologic Outcomes Following Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. Eur Urol. 2019. PMID: 31060824. doi:10.1016/j.eururo.2019.04.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。